FDA Drug Recalls

Recalls / Class II

Class IID-0434-2023

Product

Heparin Sodium, 25,000USP units per 250 mL, (100 USP units per mL) in 5% Dextrose Injection, 250 mL Excel Container, B.Braun Medical Inc, Bethlehem, PA. 18018-3524 USA. NDC 0264-9587-20.

Brand name
Heparin Sodium In Dextrose
Generic name
Heparin Sodium And Dextrose
Active ingredients
Dextrose Monohydrate, Heparin Sodium
Route
Intravenous
NDCs
0264-9567, 0264-9577, 0264-9587
FDA application
NDA019952
Affected lot / code info
Lot J2C017; Expiration: 9/30/2023.

Why it was recalled

Subpotent Drug: low Anti-Factor IIa potency.

Recalling firm

Firm
B. Braun Medical Inc
Manufacturer
B. Braun Medical Inc.
Notification channel
Letter
Address
2525 Mcgaw Ave, Irvine, California 92614-5841

Distribution

Quantity
30672
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2023-03-01
FDA classified
2023-03-06
Posted by FDA
2023-03-15
Terminated
2024-03-13
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0434-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Heparin Sodium In Dextrose · FDA Drug Recalls